Kashif Ali, MD
Hematology & Oncology · Silver Spring, MDNPI 1851423388
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $700,504 of the $987,234 with a category attached, or 71.0%. 60 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 33.5% of the total. Among hematology & oncology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,823 payments — averaging $541.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$331K
- AstraZeneca$190K
- Sanofi$183K
- Regeneron Healthcare Solutions, Inc.$88K
- Sobi, Inc$50K
- Bristol Myers Squibb$15K
- plus $129K from 54 others
Across 194 payments — averaging $1915.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$70K
- Ipsen Bioscience Inc.$67K
- AstraZeneca$64K
- Jazz Pharmaceuticals Inc.$53K
- Mirati Therapeutics, Inc.$34K
- Janssen Research & Development, LLC$25K
- plus $59K from 7 others
What the payments were for
- Consulting fees$171,83617%
- Speaking & faculty fees$700,50471%
- Travel & lodging$70,2807%
- Food & beverage$40,7204%
- Education$7290%
- Other$3,1640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$987,234 in reported general payments places this provider in the 95th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 31 | $622,380 |
| KisqaliRibociclib Succinate | 32 | $578,365 |
| XtandiEnzalutamide | 33 | $547,194 |
| Lenalidomide | 44 | $505,931 |
| JakafiRuxolitinib Phosphate | 26 | $484,977 |
| IdhifaEnasidenib Mesylate | 13 | $434,860 |
| ErleadaApalutamide | 24 | $386,227 |
| CalquenceAcalabrutinib Maleate | 23 | $341,511 |
| TagrissoOsimertinib Mesylate | 17 | $292,220 |
| SprycelDasatinib | 22 | $224,005 |
| EliquisApixaban | 303 | $212,004 |
| VerzenioAbemaciclib | 14 | $195,221 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 20 | $142,340 |
| OrgovyxRelugolix | 27 | $71,959 |
| Deferasirox | 11 | $65,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Idhifa | $15,238 | $1,057,24044 claims |
| AstraZenecaCalquence, Tagrisso | $190,047 | $633,73140 claims |
| NovartisKisqali | $4,822 | $578,36532 claims |
| Astellas Pharma US IncXtandi | $384 | $547,19433 claims |
| Incyte CorporationJakafi | $484 | $484,97726 claims |
| Johnson & JohnsonErleada, Xarelto | $6,530 | $429,28067 claims |
| PfizerEliquis, Octagam | $3,207 | $354,344323 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $331,006 | $224,00522 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $515 | $195,60449 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Silver Spring
- Courtney AckermanSilver Spring$25K
- Kashif FirozviSilver Spring$17K
- Clara ChanSilver Spring$15K
- Frederick MinSilver Spring$13K
- Ralph BocciaBethesda$3.1M
- Sandra SwainBethesda$1M
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
- Noah HahnBaltimore$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.